Increasing our understanding of pigmentary disorders - 09/08/11
Los Angeles, California; Dayton and Mason, Ohio; Dallas, Texas; New York, New York; Boca Raton, Florida; and Nice, France
Abstract |
This article focuses on developments in pigmentary disorders that extend dermatologists’ understanding of the field. Areas that are reviewed include the basic biochemistry, pharmacology, and physiology of the melanocortin system; melanosome development; genetic diseases associated with pigmentary disorders; pigmentary disorders secondary to systemic disease; drug-induced hyperpigmentation; environmental exposure to chemicals; and primary disorders of hyperpigmentation such as melasma and lentigines. Basic, clinical, and epidemiological research, along with a number of clinical case reports, were included in the review. This article also reports on the new health-related quality-of-life instrument (MELASQOL) that has been developed for women with melasma.
Le texte complet de cet article est disponible en PDF.Abbreviations used : APP, BLOC-1, DLQI, HCV, HPS, HRQoL, IM, LHS, LySD, MC1R, MSH, PDA, PJS, sAPP, UV
Plan
Supported by Galderma International. Disclosure: All authors are members of the Pigmentary Disorders Academy (PDA) and receive honoraria from Galderma for their work on behalf of the Academy. |
Vol 54 - N° 5S2
P. S255-S261 - mai 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?